In 1945, Thomas Cooley described the first cases of X-linked sideroblastic anemia (XLSA) in two brothers from a large family in which the inheritance of the disease was documented through six generations. Almost 40 years later the enzymatic defect in XLSA was identified as the deficient activity of the erythroid-specific form of S-aminolevulinate synthase (ALAS2). the first enzyme in the heme biosynthetic pathway. To determine the nature of the mutation in the ALAS2 gene causing XLSA in Cooley's original family, genomic DNAs were isolated from two affected hemizygotes, and each ALAS2 exon was PCR amplified and sequenced. A single transversion (A t o C) was identified in exon 5. The mutation predicted the substitution of leucine for phenylalanine at residue 165 (F165L) in the first highly conserved domain of the ALAS2 catalytic core shared by all species. No other nucleotide changes were found by sequencing each of the -LINKED sideroblastic anemia (XLSA) is the most common of several inherited forms of sideroblastic anemia. The first report of this metabolic disorder was by Thomas Cooley in 1945.' The same family was further described in 1946 by Rundles and Falls' and is the subject of this report. Since this time, more than 100 cases of XLSA have been de~cribed,~ demonstrating that XLSA is a clinically heterogeneous disorder of erythropoiesis characterized by hypochromic, microcytic erythrocytes; anemia; splenomegaly; elevated tissue and serum iron; and ringed sideroblasts in the marrow. Onset is typically in infancy or early childhood, and X-linked inheritance of the disorder has been established by pedigree analysis. Affected heterozygotes have been identified: as expected for lyonization in X-linked disorders. Carrier detection requires careful determination of erythrocyte size distribution if lyonization is markedly skewed toward activation of the normal allele.
Many patients with XLSA respond to oral pyridoxine therapy of 5 to 500 mg/d. Hemoglobin levels increase by varying degrees but rarely return to normal levels. Even with near normal hemoglobin concentrations, microcytic erythrocytes remain. Although transfusions are often given to correct the severe anemia, the lack of effective erythropoiesis typically leads to iron overload, requiring chelation therapy and possibly interfering with the benefits of pyridoxine therapy by disturbing mitochondrial function. Notably, phlebotomy has proven effective in obviating the iron overload without exacerbating the anemia in several case^.^.^ 6-Aminolevulinate synthase (succinyl-coenzyme A [CoA]:glycine C-succinyltransferase [decarboxylating]; EC 2.3.1.37; [ALAS]) catalyzes the first step of heme biosynthesis and requires the B6 vitamer pyridoxal 5"phosphate to accomplish the condensation of succinyl CoA and glycine to form 6-aminolevulinic acid in the mitochondria of animal cells. Two isozymes of ALAS exist in vertebrates: a housekeeping isozyme and an erythroid-specific isozyme.8-" These tissue-specific isozymes are encoded by two separate
In humans, the erythroid gene ALAS2 has been 11 exons, including intron/exon boundaries, 1 kb of 5"flanking and 350 nucleotides of 3"flanking sequence. The mutation introduced an Mse I site and restriction analysis of PCRamplified genomic DNA confirmed the presence of the lesion in the two affected brothers and in three obligate heterozygotes from three generations of this family. Carrier diagnosis of additional family members identified the mutation in one of the proband's sisters. After prokaryotic expression and affinity purification of both mutant and normal ALAS2 fusion proteins, the specific activity of the F165L mutant enzyme was about 26% of normal. The cofactor, pyridoxal 5"phosphate, activated and/or stabilized the purified mutant recombinant enzyme in vitro, consistent with the pyridoxineresponsive anemia in affected hemizygotes from this family. mapped to the distal subregion of chromosome band Xpl l.21.14 The fact that ALAS2 is on the X chromosome and that its B,-dependent enzymatic activity is often reduced in patients with XLSA15316 pointed to ALAS2 as a candidate gene for this disorder.
Recently, we reported the first mutation in ALAS2 in a patient with pyridoxine-responsive XLSA.I7 In this patient, a point mutation in exon 9, which contains the predicted pyridoxal 5"phosphate attachment site, resulted in a greater than 95% reduction of the activity of the recombinant mutant enzyme as compared with the recombinant normal enzyme. Because responsiveness of ALAS2 to pyridoxal 5"phosphate was demonstrated in vitro, the X-linked defect in ALAS2 was consistent, both genotypically and phenotypically, with XLSA in the patient. In this report, we identify and characterize a new ALAS2 mutation in three generations of the original XLSA family described by Cooley. This exon 5 point mutation results in reduced recombinant ALAS2 activity and shows activation by pyridoxal 5"phosphate in vitro. These results confirm the conclusion of Cooley and his associates that the defect was a congenital inability to synthesize hemoglobin in the face of ample iron stores.
CASE REPORTS
An extensive kindred with XLSA, now documented through eight generations (Fig l) , was the first family with XLSA to be reported, initially by Cooley in 1945' and subsequently as family I1 of Rundles and Falls in 1946.' Affected males of this kindred exhibited the classic features of anemia, peripheral erythrocyte anisocytosis and poikilocytosis, splenomegaly, and a markedly elevated serum iron level.' The first female in this large pedigree was from Holland, whereas most of the American branch of the family now resides in Michigan. Before 1945, affected males in this family usually died in their first year of life, but not later than 17 years of age, due to a severe microcytic, hypochromic anemia. Transfusion therapy was initiated in patients VI-l6 and VI-l9 (Fig l) , which resulted in clinical improvement.' At 28 years of age, one of these transfusiondependent males (VI-16) was studied in another laboratory'8 and was found to have hemosiderosis of the marrow with a hemoglobin level of 6.5 g/dL. Although he had been transfusion dependent for the previous 15 years, he was subsequently able to maintain a hemoglobin level of 7.8 to 9.6 g/dL on oral pyridoxine therapy (100 mg/ d)."
Patient VII-21. The proband for this report was patient VII-21, a first cousin once removed of the brothers reported by Cooley' (VI-16 and VI-19, Fig 1) . He was born on March 21, 1961, at the University of Michigan Medical Center and received subsequent medical care there. At birth, he weighed 2.18 kg and had a hemoglobin concentration of 7 g/dL. Peripheral blood films showed the classic microcytic, hypochromic erythrocytes with abundant anisocytes and poikilocytes, including ovalocytes and lacrimatocytes (teardrop shaped cells) (Fig 2B) . His response to vitamin B, administration and transfusion is summarized in Fig 3. Over the course of his first 21 years, the proband demonstrated a consistent but modest increase in hemoglobin concentration with vitamin B, therapy. Hemoglobin levels decreased to values of 6.5 to 7.0 g/dL when B, was withdrawn and increased to 7.5 to 9.0 g/& when B, therapy was reinstated. The mean corpuscular volume (MCV) deviated little from a median value of 56 fL/cell from 14 years of age to his most recent evaluation at 32 years of age. His reticulocyte level ranged from 0.5% to 2.2% with no obvious relationship to therapy. At 2 years of age, results of a bone marrow examination were normal. At 19 years of age, the ferritin concentration was 450 pg/L and the serum iron 263 pg/dL, with 100% transfemn saturation. The bone marrow contained large numbers of proerythroblasts, and the bone marrow stain for iron showed abundant classic ringed sideroblasts (Fig 2C) . A chromium-51 red cell survival time was 21 days (normal 26 to 30 days). Slight splenomegaly was noted for the first time at 19 years of age by scanning, giving a sp1een:liver ratio of 2.2: 1 ; compatible with hypersplenism. Fetal hemoglobin concentration was 1.8%, and hemoglobin A2 was 1.8% (normal 2.3% to 3.3%). At 21.5 years of age the liver edge was palpable 6 cm below the costal margin and the span was 10 cm. The spleen descended 6 cm below the left costal margin. Because of exertional dyspnea, a transfusion program was begun to maintain the hemoglobin concentration between 9 and 12 g/dL. At 25 years of age, with a ferritin concentration of 3,700 p g L , desfemoxamine chelation was begun. Three years later, with the development of retinopathy and type I diabetes, the transfusion and chelation therapy were discontinued. At 32 years of age, increasing the pyridoxine to 500 mg/d produced no hematologic improvement.
Patient VII-22. Patient VII-22, born 15 months after his brother, VU-21, weighed 2.32 kg and had a hemoglobin concentration of 8 g/dL. He was allegedly placed on pyridoxine intradermally at birth, but as with his brother, by 1 month of age the hemoglobin concentration had decreased to 5.2 g/dL (hematocrit 21.5%, reticulocyte count 1.9%, MCV 56.5 %/cell). He was transfused once and continued to Bs therapy, the average hemoglobin concentration was 8.5 g/&. The reticulocyte level varied between 0.6% and 2.4%, with no apparent explanation for the fluctuation. The spleen became palpable at 3.5 years of age. At 4 years of age his height was at the tenth percentile, his weight at the third percentile. At 5 years of age, when an interatrial septal defect was repaired, the spleen was palpable 4 cm below the costal margin. At 7 years of age, when an orchiopexy was performed, his height and weight were at the 25th percentile. At age 17, bone marrow examination showed a picture similar to his brother's with erythroid hyperplasia and large numbers of proerythroblasts and ringed sideroblasts. His serum iron level was 275 p&&, saturation 100%. His ferritin level was 240 p@. At 18 years of age, regular transfusions were begun because of exercise intolerance. Two years later, liver and spleen were palpable 10 cm below the costal margins. Because of dramatically increased transfusion requirements, splenectomy was performed at 20.5 years of age. Subsequently his hemoglobin decreased from 8.5 to 6.7 g/&. He then experienced repeated episodes of deep venous thrombosis, although his platelet count was only 575,000 cells/&. He transferred his medical care elsewhere from the University of Michigan and continued to have venous thrombosis and pulmonary emboli, some of which were life threatening. A bone marrow transplant was performed at another institution, and he died from graft-versus-host disease at 23 years of age.
Other relatives. During the past 20 years the blood of over 25 members of this family were studied by one of us (D.L.R.). Eight obligate heterozygotes had normal hemoglobin concentrations, although their erythrocytes contained a microcytic, hypochromic subpopulation. For example, the proband's mother (VI-5) showed a dimorphic film with only a few pale, small cells and an occasional poikilocyte, with a hemoglobin level around 12.3 g / & and an MCV of 101 %/cell (Fig 2A) . By automated red cell size analyses, the microcytes comprised approximately 10% of the red cell mass with an MCV of 50 &/cell.
MATERIALS AND METHODS
Histochemistry. Peripheral films were prepared with Wright's stain, and the bone marrow film was analyzed for iron by Perl's stain. In the latter, potassium ferrocyanide reacts with femc iron to form Prussian blue, and neutral red dye counterstains the nuclei red. The cytoplasm and hemoglobin are not stained. Photography was on Ektachrome or Fuji IS0 64 tungsten film using a Nikon Labophot-2 microscope with a Fluor 100/1.30 oil immersion objective, a 2.5X projection lens and 1.2% tube magnification for 3 13 X magnification before photographic enlargement.
Molecular analysis of the ALAS2 gene. Genomic DNA from the proband (W-21) and other family members was extracted from peripheral blood, cultured lymphoblasts, and other tissues according to standard techniques.lg DNA from the proband's deceased brother (VU-22) was extracted from his spleen which had been kept at -20°C by one of us (D.L.R.) since his splenectomy. Subcloning and sequencing of the polymerase chain reaction (PCR)-amplified ALAS2 gene exons and flanking regions was performed as previously described." Each 100-pL PCR reaction mixture contained 1 pg of genomic DNA, 100 pm01 each of the sense and antisense oligonucleotides containing EcoRI sites, 50 pmol/L each dNTP, 50 mmom KCI, 10 mmol/L Tris-HC1 (pH 9.0), 0.1% Triton X-100, .. WI). The reaction mixture was incubated at 94°C for 4 minutes, then 30 cycles of amplification were performed in a PTC-100 Programmable Thermal Cycler (MJ Research, Watertown, MA) with denaturation at 94°C for 30 seconds, primer annealing at the melting temperature (t,) of the oligonucleotide pairs for 30 seconds, and extension at 72°C for I minute. All PCR products were restricted and subcloned into pGEM-4Z (Promega). ALAS2 exon 5 was amplified (annealing temperature 62°C) with the following primers: sense 5' AGAC-TAGCCAGGGAGAGACT 3' and antisense 5' GCCGCCGAATTC-TTTCCATGTGTGGTT"C 3'. Sequences were confirmed in neered by PCR to start at Asp 79 as determined by homology to the predicted mouse erythroid ALAS N-terminus.",'3 PCR amplification was accomplished as previously described, using IO ng of template DNA (pGEM4Z-AE2) and oligonucleotides: sense 5' GATGGGAA-GAGCAAGATTGTG 3' and antisense 5' GCCGCCAAGCTTC-TCGAGGGGACAGATGGC 3' (annealing temperature 56°C). PCR products were blunt-ended using T4 DNA polymerase by incubating for 15 minutes at 15°C in 50 mmol/L NaCI, 10 mmol/L Tris-HCI, 10 mmol/L MgClz, 1 mmol/L DTT, 125 pmol/L of each dNTP and 3 U T4 DNA polymerase (New England Biolabs). The enzyme was multiple subclones if differences were found from our published inactivated by incubating at 100°C for 5 minutes. The blunt-ended sequence." The numbering of the complementary DNA (cDNA) PCR products were restricted with Xho 1, gel-purified, and cloned previously usedt7 has been corrected by adding five nucleotides (nt)
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into Xmn IIXho I-restricted and gel-purified pMALc2-AEI. The to include an upstream in-frame methionine identified in the genomic F165L mutation was initially introduced into the pET5a-AE2I7 clone sequence (Bishop, unprlhlished observations) and not present in the reported cDNA clone." Primer extension studies (Bishop, unpublished observations) identified this as the first methionine after the CAP site, confirming the result of Cox et al. '3 Products from PCR amplification of ALAS2 exon 5 were restricted with 4 U Mse I (New England Biolabs, Beverly, MA). All restriction digests were electrophoresed in 2% agarose (Ultra Pure grade, GIBCO BRL, Gaithersburg, MD) gels containing 0.1 pg/ml ethidium bromide and photographed on a Fotodyne UV Transilluminator with Polaroid Type 57 film.
by site-directed mutagenesis using the PCR ovcrlap mcthodZ4 to yield the clone pET5a-AE7. The Xtnn YXho 1 fragment from pET5a-AE7 was cloned into Xmn IIXho I-restricted and gel-purified pMALc2-AE2. The resulting clones, pMALc2-AE2 and pMALc2-AE7, were sequence confirmed.
The pMALc2-AE2 and pMALc2-AE7 expression constructs were transfected into Escherichiu coli BL2 I , pLysS (Novagen, Madison, WI) and overnight cultures grown in LB (GIBCO BRL) media with 50 pglmL ampicillin (Sigma, St Louis, MO) and 34 pglml chloramphenicol (Sigma). The next day, 100-mL cultures in LBlampicillin Protein homology comparisons and secondary structure predicmedia were initiated with a 1:40 dilution of the overnight cultures tions were performed with the PILEUP program of the Genetics and grown to 0.4 A, units. Induction with 0.4 mmol/L isopropyl Computer Group (GCG) Sequence Analysis Software Package"' and 0-D-thiogalactopyranoside was performed in LBIampicillin media with the Predictprotein program,*' respectively.
for 4 hours at 37°C. Cells were pelleted at 4 , 0 0 0~ for 15 minutes, Expression ofthe nomulandF165LAUS2 enzymes. Recombiresuspended in 5 mL of SO mmol/L HEPESlpH 7.5, 1 mmol/L nant normal and mutant ALAS2 were generated using the pMAL EDTA, 5 mmol/L DTT, and frozen at -7OT for at least 1 hour. fusion protein expression system (New England Biolabs). resulting MgCIZ, RNase A (Sigma), and DNase I (Sigma) were added to the in maltose binding protein (MBP) attached to the N-terminus of thawed lysate to final concentrations of 1 mmol/L, 200 pgImL, and ALAS2 with a Factor Xa-cleavable linkage. The EcoRl fragment 20 pglmL, respectively. The lysate was incubated for 20 minutes at from pGEM4Z-AE2" was initially subcloned into EcoRI-restricted room temperature, then centrifuged at 4°C for 30 minutes at 10,000~. pMAL-c2 (New England Biolabs) to yield the clone pMALc2-AEI.
The supernatant was retained, filtered through a 0.45-pm filter (GelThe 5' end of the ALAS2 portion of the fusion protein was engiman, Ann Arbor, MI) to yield the crude E coli extract. This was ALAS activity was assayed as previously described" with detection by Ehrlich's reagent after reaction with ethyl acetoacetate." One unit of activity is that amount of enzyme required to catalyze the production of I nmol of 6-aminolevulinate per hour under the conditions of the assay. Protein concentration was determined by a modification of the Ruorescamine method." Both the normal and F16SL fusion proteins were assayed at various concentrations of added pyridoxal S'-phosphate (PLP).
RESULTS

Characterization of
the ALAS2 mutation. Genomic DNA from peripheral blood was isolated from patient VII-2 1. Each exon of the ALAS2 gene, including 50 to 150 nt of flanking intron sequence, 1 kb of 5', and 350 nt of 3' flanking sequence, was PCR-amplified and sequenced. A single base change in exon 5 was the only difference from the normal sequence. This C-to-A transversion at nt 547 (Fig  4) predicted the substitution of leucine for phenylalanine at residue 165 (F165L) and introduced an Mse I site. PCRamplified exon 5 from 50 unrelated white females was restricted with Mse I and analyzed by agarose gel electrophoresis for detection of the predicted normal 325-bp or mutant 208-bp and 117-bp fragments. The absence of restriction in 1 0 0 alleles demonstrated that the mutation was not a common polymorphism (data not shown).
Restriction analysis of exon 5 amplified genomic DNA from family members demonstrated 100% concordance between the presence of the Mse I site and a microcytic, hypochromic red blood cell population in affected hemizygotes and obligate heterozygotes. X-linked inheritance of the F165L mutation was demonstrated in three generations. The proband, his grandmother, mother, aunt, sister, and brother all had been previously diagnosed as hemizygotes or carriers, and all had the mutation as evidenced by 208 bp and 1 17 3' 
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bp Mse I restriction fragments (Fig 5) . Two phenotypically normal sisters and an unaffected nephew all lacked the mutation as demonstrated by uncut 325-bp fragments (Fig 5) .
Expression and characterization of recombinant normal and mutant fusion proteins. Recombinant normal and F165L ALAS2 proteins were expressed in E coli as fusion proteins with the maltose-binding protein (MBP) using the pMAL expression system. Previous expression of recombinant ALAS2 in the pET5a system" resulted in only a small fraction (less than 0.1 %) of soluble recombinant ALAS2, the remainder being localized in inclusion bodies. Expression of recombinant ALAS2 as a fusion with the 43-kD MBP resulted in greater than 10% of the predicted 90-kD ALAS2 fusion protein remaining soluble in the supernatant. The MBP moiety also allowed partial purification by affinity chromatography using an amylose resin (Fig 6) . Crude extract and affinity-purified normal and mutant ALAS2 fusion proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 10% gels with a 3% stacking gel according to the method of Laemmli and Favre." Approximately 1 0 0 pg of crude extract and 4 pg of affinitypurified fusion protein were applied to each well. The 14-to 94-kD protein molecular weight standards (Pharmacia, Piscataway, NJ) were in the first and last wells (Fig 6) . Although similar amounts of both recombinant normal and mutant 90-kD fusion proteins were visible in the gel for the crude extracts, the amount of F165L mutant fusion protein was reduced relative to normal for the affinity-purified material. Extracts from cells lacking the pMAL fusion construct lacked the 90-kD band (data not shown). The specific activity of the purified mutant ALAS2 was about 26% of the purified normal enzyme. Because the 90-kD mutant band was also reduced in intensity to about one third of the normal band in the affinity-purified lanes (Fig 6) , it is possible that the mutation affects stability. The presence of the fusion protein on the aminoterminus of the ALAS2 protein apparently does not inhibit activity because the specific activity was unchanged after complete cleavage by factor Xa (data not shown). 
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Effect of PLP on normal and mutant ALAS2 activity. The affinity-purified recombinant normal and F165L fusion proteins were assayed with 0 or 5 pmol/L PLP after two and three freeze-thaw cycles ( Table 1) . The residual specific activity of the F165L enzyme at 0 pmol/L added PLP was 13% that of the normal enzyme and at 5 pmoVL PLP averaged 26%. The specific activity of the normal MBP-ALAS2 protein increased about 9% from 0 to 5 pmoVL added PLP. In contrast, the specific activity of the F165L MBP-ALAS2 fusion protein increased over twofold in the presence of 5 pmol/L PLP. The addition of protease inhibitors in the assay had no effect, suggesting that PLP activated or stabilized the enzymes rather than protected them against proteolysis.
Homology comparison and secondary structure prediction. Homology comparisons of human ALAS2 exon 5 with 14 other ALAS sequences, using the PILEUP program of the GCG package,*' demonstrated that the mutation occurred in a region that was well conserved (Fig 7) and that the mutated phenylalanine residue was invariant in all but the chick erythroid sequence. The beginning of exon 5 corresponds to the aminoterminus of prokaryotic ALAS sequences, suggesting that exons 5 through 1 1 constitute the essential catalytic region of the enzyme. The F165L mutation occurs within 22 residues of the beginning of exon 5 and is the most aminoterminal mutation found to date in patients with XLSA.
Secondary structure predictions for the region of exon 5 surrounding the mutation were obtained with version 11.93 of the PHD program of Rost and Sander." The expected accuracy was about 6 4 % because the program was run without comparison to ALAS homologues. Although the normal sequence predicted a transition from &sheet to a-helix structure in the region of F165 (data not shown), the F165L mutation resulted in a prediction of all a-helix structure in this region. Although this predicted structural change was consistent with the altered phenotype, accurate correlation awaits tertiary structure determination. 
DISCUSSION
In 1945, Cooley described "a severe type of hereditary anemia with elliptocytosis."' This first reported case of what is now known as XLSA has been shown here to be caused by a point mutation in the ALAS2 gene. An F165L mutation was identified in the proband (VII-21) and his affected brother (VII-22). descendants of the family members originally studied by Cooley.' In this family, the Mse I site created by the mutation provided definitive heterozygote diagnosis. All tested female family members with dimorphic erythrocyte populations were confirmed heterozygous for the F165L mutation, and all individuals tested in this pedigree with normal red cell populations lacked the F165L mutation. The X-linked inheritance of this specific ALAS2 mutation was established through three generations of this large kindred.
Normal and mutant ALAS2 were expressed from the pMAL-c2 vector in E coli as maltose binding protein (MBP)-ALAS2 fusion proteins and affinity purified for enzymatic characterization. Perhaps due to the fact that a substantial part of the aminoterminal region may be unnecessary for catalytic activity (absent in prokaryotes), the presence of the maltose binding protein did not significantly reduce ALAS2 catalysis: it could be cleaved with Factor Xa with no change in ALAS2 activity (data not shown). The fusion protein helped maintain the enzyme in a soluble form and facilitated affinity purification with an amylose resin column. The final specific activity of the normal enzyme, which was estimated to be about 70% pure (Fig 6) , was about 20,000 U h g . This was over 100-fold more active than the homogeneous murine erythroid ALAS22' and may reflect loss of murine ALAS2 activity during purification involving denaturation and renaturation from inclusion bodies.
The effect of PLP on ALAS2 enzymatic activity was characterized for the normal and mutant recombinant enzymes. Assayed in the presence of 5 pmoln PLP, the F165L enzyme had about 26% residual specific activity relative to the normal enzyme after affinity purification. The presence of muta- 
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Affinity Purified tion-specific lower molecular weight species in this preparation suggested that the mutant enzyme may be more susceptible to degradation during purification. It also may be more susceptible to inactivation by loss of the PLP moiety because addition of PLP resulted in over 110% activation as opposed to a 9% activation for the normal enzyme. Our working hypothesis is that the mutation alters the local secondary structure and possibly perturbs the overall conformation decreasing stability and/or reducing the affinity for PLP. The activating and/or stabilizing effect of PLP may be the explanation for the modest increase in hemoglobin seen in hemizygotes after pyridoxine supplementation. Additional PLP binding studies and stability experiments with homogeneous normal and mutant ALAS2 will be needed to test this hypothesis.
Comparison of all reported ALAS sequences demonstrated that the phenylalanine at residue 165 was highly conserved. When the 15 published amino acid sequences for the ALAS2 and ALAS 1 isozymes were aligned in the region of the F165L mutation, phenylalanine 165 was invariant in all sequences except that for the chicken erythroid isozyme (Fig  7) . The immediate context was also highly conserved as compared with flanking sequences, suggesting that this domain is important for enzyme structure and/or catalytic activity. Although there are 139 and 193 amino acids in human erythroid and hepatic ALAS I , respectively, before the beginning of the residues encoded by exon 5, the beginning of all six of the bacterial peptides corresponds to the fourth residue of this exon (Fig 7) . Thus, it is expected that phenylalanine 143 defines the minimal aminoterminal boundary of the region of the ALAS2 peptide required for catalytic activity. The F165L mutation is the most aminoterminal ALAS2 mutation identified to date and occurs in the first highly conserved domain of this catalytically competent core. The secondary structure prediction program of Rost and Sander?' predicted that the F165L mutation would introduce a local change from &sheet to a-helix in the region of the mutation. This could provide a mechanism for the observed reduced stability of the F165L recombinant ALAS2 fusion protein.
Our case studies confirm and extend the original report by Cooley' and demonstrate that this family is a classic example of XLSA. Hemizygotes presented at birth with predominantly microcytic, hypochromic erythrocytes of variable shapes and sizes, and their anemia showed a moderate response to pyridoxine therapy, as was previously demonstrated in this family." Iron overload became significant with time as evidenced by abundant ringed sideroblasts in the marrow, elevated plasma ferritin, and saturated plasma transferrin. The obligate heterozygotes were uniformly dimorphic in peripheral blood cell size, although this was often a small population. This result could be due to skewed lyonization, impaired hematopoiesis, or diminished survival of the erythrocytes derived from the mutant allele. Diagnosis of XLSA was aided by careful determination of MCV and/or red cell distribution width in mothers and female relatives of affected individuals.
The moderate in vitro response of the recombinant F16SL enzyme to PLP was mirrored in the partial clinical response of affected males in this family to pyridoxine supplementation and appeared to be compromised by iron overload. For example, patient VII-21 showed repeated response to PLP or pyridoxine therapy and was able to maintain a hemoglobin of 8 to 9 g/dL for 16 years on 25 to 50 mg pyridoxineld and even in the absence of pyridoxine for a decade, until he was placed on a transfusion program due to exercise intolerance (Fig 3 ) . The patient's 16-year period with tolerable anemia was significant because previously males in this family, if untreated by pyridoxine or transfusion, typically died in the first year of life (Fig l) . It is not clear why the brothers became so anemic in the first month of life, even while receiving pyridoxine. The fluctuations in hemoglobin concentration, with or without pyridoxine administration, are unexplained, as is the seemingly greater response to pyridoxine of VII-21 than his brother. Their splenic involvement also differed, the spleen becoming palpable at least 3.5 years earlier in VI-22 and requiring removal after transfusions were initiated.
Although transfusions immediately alleviated the anemia, the subsequent increase in mitochondrial iron stores may have compromised what limited heme synthetic capacity was available. The cause of death in XLSA patients, other than of severe anemia in infancy, is often due to progressive iron overload.' Several reports have highlighted the value of phlebotomy to remove excess iron in XLSA patient^.'"^^^ In For personal use only. on August 30, 2017. by guest www.bloodjournal.org From these cases, repeated phlebotomy resulted in reduced iron levels without adversely affecting hemoglobin concentration, indicating that stored iron was capable of being mobilized for bone marrow hemoglobin production and that the bone marrow was capable of responding to blood loss despite the limitation to erythrop~iesis.~"~~~ Significantly, patients who were previously refractory to pyridoxine therapy became responsive after the iron stores were d e~l e t e d .~.~
In this and our previous study" we have demonstrated an in vitro response to PLP of the mutant recombinant enzymes consistent with the clinical response to pyridoxine seen in the patients. In addition, we have reported in abstracts the existence of four additional unrelated XLSA families with unique pyridoxine-responsive ALAS2 mutation^,^^.^' and others have reported in abstracts four mutations in five families, one of which was suggested not to be pyridoxine respon~i v e .~' .~~ Thus, mutations causing this disorder seem to be largely private.
If X-linkage is not demonstrated, hereditary sideroblastic anemia refractory to pyridoxine is most likely due to some other cause, and we recently reported exclusion of X-linkage for pyridoxine-refractory hereditary sideroblastic anemia, with evidence for autosomal inheritan~e.~~
In conclusion, we have reported a new mutation in the erythroid-specific ALAS2 gene in a large kindred with moderately pyridoxine-responsive XLSA and have demonstrated an in vitro activation of the F165L recombinant mutant enzyme by PLP. This was the first XLSA family to be described in the literature,'.' and their mutation has now been identified and confirms the involvement of the X-chromosomal ALAS2 gene in the etiology of XLSA.
